Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 17, 2023 - Issue
Submit an article Journal homepage
137
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Effect of Dezocine on the Median Effective Dose of Sufentanil-Induced Respiratory Depression in Patients Undergoing Spinal Anesthesia Combined with Low-Dose Dexmedetomidine

Yong-Kang Gui1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of ChinaView further author information
,
Xiao-Hui Zeng1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of ChinaView further author information
,
Rui Xiao3 Department of Anesthesiology, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, 236113, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9396-4148View further author information
ORCID Icon,
Wen-Feng Xi1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;3 Department of Anesthesiology, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, 236113, People’s Republic of ChinaView further author information
,
Dan Zhang1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;3 Department of Anesthesiology, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, 236113, People’s Republic of ChinaView further author information
,
Yang Liu1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of ChinaView further author information
,
Si-Hui Zhu1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-2374-1763View further author information
ORCID Icon,
Xin Da1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1017-443XView further author information
ORCID Icon,
De-Wen Shi1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of ChinaView further author information
,
Xu-Dong Hu1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of ChinaView further author information
&
Guang-Hong Xu1 Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of China;2 Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, 230022, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 3687-3696 | Received 01 Aug 2023, Accepted 19 Nov 2023, Published online: 07 Dec 2023

Abstract

Purpose

The application of sedation and analgesia in spinal anesthesia has many benefits, but the risk of respiratory depression (RD) caused by opioids cannot be ignored. We aimed to observe the effect of dezocine, a partial agonist of μ-receptor, on the median effective dose (ED50) of sufentanil-induced RD in patients undergoing spinal anesthesia combined with low-dose dexmedetomidine.

Patients and Methods

Sixty-two patients were randomly assigned to dezocine group (DS) and control group (MS). After spinal anesthesia, mask oxygen (5 L/min) and dexmedetomidine (0.1 ug/kg) were given. Five minutes later, patients in the DS group received an Intravenous (IV) bolus of sufentanil and 0.05mg/kg dezocine, while patients in the MS group only received an IV bolus of sufentanil.

Results

ED50 of DS group was 0.342 ug/kg, 95% confidence interval (CI) was (0.269, 0.623) ug/kg, and the ED50 of MS group was 0.291 ug/kg, 95% CI was (0.257, 0.346) ug/kg. There was no difference in the type and treatment measures of RD and hemodynamic changes between the two groups, and no serious adverse reactions occurred in either group.

Conclusion

Dezocine can improve RD induced by sufentanil in patients with spinal anesthesia combined with low-dose dexmedetomidine, and increase the safety window of sufentanil use.

Introduction

Spinal anesthesia (SA) is a conventional technique in which a local anesthetic is administered in the cerebrospinal fluid (CSF) within the lumbar spine. This procedure effectively anesthetizes the nerves exiting the spinal cord, resulting in pain relief and subsequent muscle relaxation within the corresponding spinal innervation region. This technique is widely used in obstetrics and gynecology,Citation1–7 pediatrics,Citation8,Citation9 orthopedics,Citation10,Citation11 and urology as well as in various surgical procedures.Citation12,Citation13 However, as individuals undergoing SA remain conscious throughout the procedure, this can often cause intraoperative anxiety. To address this issue, additional measures involving the use of analgesics and sedatives are warranted.

Sufentanil, a frequently used fentanyl drug in clinical settings, mainly exerts its effects on μ-receptors.Citation14 Nevertheless, opioids exert an inherent respiratory depression (RD) effect,Citation15 and when used improperly, they not induce adequate analgesia and sedation but lead to severe adverse reactions.Citation16 In China, dezocine is currently the most widely used opioid. It is often administered in conjunction with other opioids to enhance its efficacy or mitigate the occurrence of adverse reactions.Citation17 Dexmedetomidine, which is a novel selective α-2 adrenergic receptor agonist,Citation18 can extend the duration of sensory block and delay the time of first remedial analgesia after SA. Therefore, it is frequently used as an adjunctive agent in the field of SA.Citation19,Citation20

The 50% effective dose (ED50) of sufentanil to induce RD when administered in a combination with dezocine and dexmedetomidine during SA remains unclear. Previous research has suggested that partial agonists of μ-receptors can mitigate opioid-induced RD.Citation21,Citation22 Hence, we postulated that dezocine, a partial agonist of μ-receptors, can mitigate sufentanil-induced RD and enhance the ED50 of sufentanil to induce RD when combined with a small dose of dexmedetomidine in patients undergoing SA.

Methods

This study was approved by the Ethics Committee of Fuyang Hospital of Anhui Medical University (KY202206, 2022/07/20), and was registered in the Chinese Clinical Trial Registry before enrollment (registration number: ChiCTR2200063386, 2022/09/05). This study was in full compliance with the Declaration of Helsinki.

Study Participants

The trial was conducted at Fuyang Hospital of Anhui Medical University from October 2022 to March 2023. Sixty patients, aged 18–60 years, American Society of Anesthesiologists (ASA) physical status I–II, body mass index (BMI) 18.5–27 kg/m2, scheduled for SA were enrolled in this study. Patients with long-term use of psychotropic drugs, a history of alcohol abuse, heart, lung, liver, kidney, neurological dysfunction, and severe drug allergy were not included. Patients with unsatisfactory spinal anesthesia level, severe adverse reactions, and incomplete records of the Case Report Form (CRF) were excluded.

Written informed consent was obtained from all patients participating in this experiment.

Randomization and Blinding

Patients were randomly assigned to the dezocine (DS) and control (MS) groups using the random number table method. The numbers were placed inside opaque envelopes, which were opened by the anesthesiologist once the patient entered the operating room and the drugs was prepared according to the numbers in the envelope.

To ensure unbiased evaluation, an investigator who was blinded to the group assignments performed respiratory monitoring for 10 min. This approach helped minimize potential observer bias.

Furthermore, all SA procedures in this study were performed by the same experienced anesthesiologist to ensure uniformity and reduce the impact of interoperator variability on the results.

Anesthesia Procedure

Blood pressure (BP), electrocardiogram, pulse oxygen saturation (SpO2), and end-tidal carbon dioxide partial pressure (PETCO2) were monitored on admission. Subarachnoid puncture was performed at the lumbar 2/3 interspace (L2/3) in the left lateral position. CSF reflux indicated a successful puncture. Next, 2 ml of 0.5% ropivacaine was injected within 10s and the sensory level was controlled in the supine position to the plane of the tenth thoracic vertebra (T10). After the plane was fixed, mask oxygen inhalation was administered at 5 L/min. The DS group was administered dexmedetomidine (0.1 µg/kg) for 5 min, followed by dezocine (0.05 mg/kg) and sufentanil. Conversely, the MS group received dexmedetomidine (0.1 µg/kg) for 5 min, followed by sufentanil. The dose of sufentanil was determined using the Dixon up–down method and the occurrence of RD. Based on the preliminary experiment, the first dose of sufentanil was selected (0.3 and 0.245 µg/kg in the DS and MS groups, respectively). The adjacent dose ratio was 1.1. If the patient exhibited RD within a span of 10 min after sufentanil infusion, the dose for the next patient was reduced by one level; otherwise, it was increased by one level. The experiment was terminated when there were seven crossovers of positive to negative alteration.

Criteria for Respiratory Depression

RD was diagnosed if one or more of the following conditions were observed: respiratory rate (RR) ≤ 8 times/min, apnea ≥ 15s, SpO2 ≤ 90%, PETCO2 ≥ 55 mmHg, arterial PaCO2 (partial pressure of carbon dioxide) ≥ 55 mmHg, and complaints of dyspnea.Citation23

Management Measures After Respiratory Depression and Significant Hemodynamic Changes

When a patient experienced RD, the following treatments were gradually provided in the mentioned order until the resolution of RD or hypoxia symptoms: 1) increased oxygen flow (5 L/min), 2) language and physical stimulation, 3) lifting of the jaw, 4) mask-assisted ventilation, and 5) artificial airway implantation (laryngeal mask/tracheal intubation).

When the patient’s heart rate (HR) was <50 beats per minute and blood pressure (BP) was >30% of the baseline value, intravenous atropine and ephedrine were administered, respectively.

Observing Indicators

The primary outcome of this study was the ED50 of sufentanil in the two groups at the end of the study. The secondary outcomes were the dose of ropivacaine, level of anesthesia, Ramsay score, vital signs (such as BP, HR, RR, SpO2, and PETCO2), and incidence of adverse reactions (SA-related complications, HR and BP drop, dizziness, headache, nausea, vomiting, etc.) recorded during the trial.

Statistical Analysis

Based on the methods used by Wu and Oh TK et al,Citation24,Citation25 and a previous study involving 13 subjects, we determined that the mean dose of sufentanil required to induce RD in patients undergoing SA was 0.291 µg/kg (SD= 0.0495), when not combined with dezocine. We believe that a 10% sufentanil dose difference between the two groups indicates that the use of dezocine is meaningful for the antagonistic potency of sufentanil-induced RD. Assume a type I error of 0.05 (Alpha= 0.05) and a power of 0.9 (1-Beta= 0.9). Considering a dropout rate of 20%, we aimed to enroll 31 patients in each group.

Statistical analysis of the data was performed using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA) V26.0. The normality of distribution was assessed using the Shapiro–Wilk test. Patient’s characteristics were compared between the two groups using the independent-sample t-test for continuous variables with normal distribution and the Mann–Whitney U-test for those with nonnormal distribution. For categorical variables, Pearson’s χ2 test was used as appropriate.

Hemodynamic indices were tested via repeated measures analysis of variance. Normally distributed and skewed data were expressed as mean ± standard deviation and median (interquartile range), respectively. Count data were tested using the chi-squared test. The significance level for all statistical tests was set at P ≤ 0.05.

Results

A total of 62 eligible patients who provided written informed consent were evaluated. They were sequentially selected until seven crossovers were attained. One patient in the MS group and another in the DS group were excluded because of unsatisfactory block plane and incomplete experimental data recording, respectively. Thus, 51 patients (DS group, 24; MS group, 27) were included in the final analysis. (). All SA procedures in this study were successfully performed by one same experienced anesthesiologist.

Figure 1 Flow diagram for the Dixon up-and-down method.

Abbreviations: DS, dezocine group; MS, control group; positive, presence of respiratory depression; negative, absence of respiratory depression.
Figure 1 Flow diagram for the Dixon up-and-down method.

Figure 2 Response in DS Group.

Abbreviations: DS, dezocine group; positive, presence of respiratory depression; negative, absence of respiratory depression.
Figure 2 Response in DS Group.

Figure 3 Response in MS Group.

Abbreviations: MS, control group; positive, presence of respiratory depression; negative, absence of respiratory depression.
Figure 3 Response in MS Group.

As shown in , the demographic characteristics of the two groups of patients were similar. The gender composition and the level of spinal anesthesia were similar between the two groups. Ramsay scores were similar in both groups. No significant difference was observed in the doses of dexmedetomidine and ropivacaine in the two groups.

Table 1 Drugs and Social Demographic Variable of Participants

Using the Dixon up–down method,Citation26,Citation27 the ED50 values in the DS and MS groups were found to be 0.342 µg/kg (95% confidence interval [CI], 0.269–0.623) and 0.291 µg/kg (95% CI, 0.257–0.346), respectively. ().

Figure 4 Dose-effect curve. According to the results of DIXON’s up-and-down method, the dose-effect curve of sufentanil induced respiratory depression was drawn to predict the adverse reactions of the two groups.

Abbreviations: DS, dezocine group; MS, control group.
Figure 4 Dose-effect curve. According to the results of DIXON’s up-and-down method, the dose-effect curve of sufentanil induced respiratory depression was drawn to predict the adverse reactions of the two groups.

No significant difference was observed in the occurrence and treatment of RD, hemodynamic changes, and incidence of adverse reactions between the two groups the during the experimental observation period. ().

Table 2 The Types of Respiratory Depression

Table 3 The Management Measures of Respiratory Depression

Table 4 Hemodynamic Measures

Discussion

SA is widely used in various surgeries. Patients undergoing SA remain conscious throughout the operation, which results in certain drawbacks such as needle-related apprehension and recollection of the surgical process.Citation28,Citation29 These are important sources of fear and anxiety for the patients,Citation30 further highlighting the importance of sedation. An appropriate sedation can provide analgesia and amnesia as well as relieve anxiety and fear. Sedation can improve patient’s satisfaction with regional anesthesia and increase patient acceptance of the associated techniques.Citation31 Consequently, the use of appropriate sedation and analgesia techniques can significantly improve the comfort of patients when undergoing SA, effectively alleviating their anxiety and fear.

Dezocine is the most extensively used opioid in China, accounting for 44% of the national opioid analgesic market.Citation32 It has weaker RD effects than commonly used μ-receptor agonists, such as fentanyl. Furthermore, it exerts a “capping effect”.Citation17,Citation33–35 The receptor profile of dezocine differs from that of known pure μ-agonists; therefore, it is allowed to be used in a combination with other opioids to improve efficacy or reduce the occurrence of adverse effects.Citation17 For example, dezocine can reduce the incidence of postoperative delirium when used during the induction of anesthesiaCitation36 and exert therapeutic effects on depression.Citation37,Citation38

Buprenorphine, a partial agonist of opioid receptors,Citation39 can reverse opioid-induced RD in humans and animals.Citation40,Citation41 Because dezocine is also a partial agonist of μ-receptors, we used it in combination with sufentanil and concluded that dezocine could partially antagonize sufentanil-induced RD in SA. This effect may be attributed to the role of dezocine as a partial agonist of μ-receptors, where it may block or displace the binding of pure opioid receptor agonist to the μ-receptor when combined with dezocine. This mechanism is similar to that observed in a previous study and provides a plausible explanation for the observed increase in the ED50 in the DS group.Citation17

The dose–response curve of a drug is usually S-shaped. The median ED50 is located at the midpoint of the curve, which indicates the dose that produces a positive response for 50% of individuals. Thus, it is often used as an index to reflect the potency of drug action.Citation42

The difference in ED50 and amount of sufentanil used between the groups in this trial also confirmed that dezocine can decrease the ED50 of sufentanil-induced RD in patients undergoing SA. The implications of this finding within the field of SA are profound, as it demonstrates the potential of the combined use of sufentanil and dezocine to simultaneously minimize the incidence of RD while providing adequate sedation and analgesia. This undoubtedly expands the safety threshold of sufentanil administration during SA.

All patients with RD exhibited decreased RR, and similar observation was reported by Smart et al,Citation43 and suggests that respiratory cycle monitoring can be used as a sensitive indicator of sufentanil-induced RD. suggesting that respiratory cycle monitoring can be used as a sensitive indicator of sufentanil-induced RD. When RD occurs, increased inspired oxygen concentration and speech stimulation could effectively improve the ventilation of patients. Similar to previous studies,Citation44,Citation45 only one patient in this study required jaw lifting to maintain satisfactory ventilation after the above treatments, but none required artificial airway implantation.

This study has several limitations. First, the results only apply to patients undergoing SA and are not a reference for the ED50 of sufentanil to induce RD under the same drug combination in patients in whom other anesthesia techniques are used. Second, this study was majorly conducted in the Han and Yellow race, and further experiments may be warranted to explore the ED50 of sufentanil under similar clinical conditions in other ethnic groups and races.

Conclusion

In conclusion, the use of dezocine can increase the ED50 of sufentanil to induce RD in patients undergoing SA combined with low-dose dexmedetomidine. This may be related to the competitive inhibition of μ-receptors by dezocine.

Data Sharing Statement

Under reasonable requirements, the data and material of this study can be obtained from the corresponding author. The data are not publicly available due to privacy restrictions.

Disclosure

The authors declare no conflicts of interest in this work.

Acknowledgments

The research team greatly appreciates the funding support, and the research participants for their cooperation and support.

Additional information

Funding

This work was supported by the National Natural Science Foundation of China (No. 81870837).

References

  • Abdallah FW, Halpern SH, Margarido CB. Transversus abdominis plane block for postoperative analgesia after caesarean delivery performed under spinal anesthesia? A systematic review and meta-analysis. Br J Anaesth. 2012;109(5):679–687. doi:10.1093/bja/aes279
  • Carney J, Finnerty O, Rauf J, Bergin D, Laffey JG, Mc Donnell JG. Studies on the spread of local anaesthetic solution in transversus abdominis plane blocks. Anaesthesia. 2011;66(11):1023–1030. doi:10.1111/j.1365-2044.2011.06855.x
  • Eslamian L, Jalili Z, Jamal A, Marsoosi V, Movafegh A. Transversus abdominis plane block reduces postoperative pain intensity and analgesic consumption in elective cesarean delivery under general anesthesia. J Anesth. 2012;26(3):334–338. doi:10.1007/s00540-012-1336-3
  • Kanazi GE, Aouad MT, Abdallah FW, et al. The analgesic efficacy of subarachnoid morphine in comparison with ultrasound-guided transversus abdominis plane block after cesarean delivery: a randomized controlled trial. Anesth Analg. 2010;111(2):475–481. doi:10.1213/ANE.0b013e3181e30b9f
  • Loane H, Preston R, Douglas MJ, Massey S, Papsdorf M, Tyler J. A randomized controlled trial comparing intrathecal morphine with transversus abdominis plane block for post-cesarean delivery analgesia. Int J Obstet Anesth. 2012;21(2):112–118. doi:10.1016/j.ijoa.2012.02.005
  • McDermott G, Korba E, Mata U, et al. Should we stop doing blind transversus abdominis plane blocks? Br J Anaesth. 2012;108(3):499–502. doi:10.1093/bja/aer422
  • Tan TT, Teoh WH, Woo DC, Ocampo CE, Shah MK, Sia AT. A randomised trial of the analgesic efficacy of ultrasound-guided transversus abdominis plane block after caesarean delivery under general anaesthesia. Eur J Anaesthesiol. 2012;29(2):88–94. doi:10.1097/EJA.0b013e32834f015f
  • Kachko L, Birk E, Simhi E, Tzeitlin E, Freud E, Katz J. Spinal anesthesia for noncardiac surgery in infants with congenital heart diseases. Paediatr Anaesth. 2012;22(7):647–653. doi:10.1111/j.1460-9592.2011.03769.x
  • Trifa M, Tumin D, Whitaker EE, Bhalla T, Jayanthi VR, Tobias JD. Spinal anesthesia for surgery longer than 60 min in infants: experience from the first 2 years of a spinal anesthesia program. J Anesth. 2018;32(4):637–640. doi:10.1007/s00540-018-2517-5
  • Brueckner S, Reinke U, Roth-Isigkeit A, Eleftheriadis S, Schmucker P, Siemens HJ. Comparison of general and spinal anesthesia and their influence on hemostatic markers in patients undergoing total hip arthroplasty. J Clin Anesth. 2003;15(6):433–440. doi:10.1016/s0952-8180(03)00082-5
  • Maurer SG, Chen AL, Hiebert R, Pereira GC, Di Cesare PE. Comparison of outcomes of using spinal versus general anesthesia in total hip arthroplasty. Am J Orthop. 2007;36(7):E101–6.
  • Alavi CE, Asgari SA, Falahatkar S, et al. Effectiveness of spinal anesthesia combined with obturator nerve blockade in preventing adductor muscle contraction during transurethral resection of bladder tumor. Turk J Urol. 2017;43(4):507–511. doi:10.5152/tud.2017.96992
  • Lie SA, Wong SW, Wong LT, Wong TGL, Chong SY. Practical considerations for performing regional anesthesia: lessons learned from the COVID-19 pandemic. Can J Anaesth. 2020;67(7):885–892. doi:10.1007/s12630-020-01637-0
  • Maciejewski D. Sufentanil in anaesthesiology and intensive therapy. Anaesthesiol Intensive Ther. 2012;44(1):35–41.
  • Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112(1):226–238. doi:10.1097/ALN.0b013e3181c38c25
  • Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012;18(37):5994–6004. doi:10.2174/138161212803582469
  • Ye RR, Jiang S, Xu X, Lu Y, Wang YJ, Liu JG. Dezocine as a potent analgesic: overview of its pharmacological characterization. Acta Pharmacol Sin. 2022;43(7):1646–1657. doi:10.1038/s41401-021-00790-6
  • Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs. 2015;75(10):1119–1130. doi:10.1007/s40265-015-0419-5
  • Abdallah FW, Abrishami A, Brull R. The facilitatory effects of intravenous dexmedetomidine on the duration of spinal anesthesia: a systematic review and meta-analysis. Anesth Analg. 2013;117(1):271–278. doi:10.1213/ANE.0b013e318290c566
  • Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013;110(6):915–925. doi:10.1093/bja/aet066
  • Moss LM, Algera MH, Dobbins R, et al. Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. PLoS One. 2022;17(1):e0256752. doi:10.1371/journal.pone.0256752
  • Olofsen E, Algera MH, Moss L, et al. Modeling buprenorphine reduction of fentanyl-induced respiratory depression. JCI Insight. 2022;7(9). doi:10.1172/jci.insight.156973
  • Egan Talmage D, Warner David O. Miller’s Anesthesia. Anesthesiology. 2005;103(3):673. doi:10.1097/00000542-200509000-00044
  • Wu Y, Jin S, Zhang L, et al. Minimum alveolar concentration-awake of sevoflurane is decreased in patients with end-stage renal disease. Anesth Analg. 2019;128(1):77–82. doi:10.1213/ANE.0000000000003676
  • Oh TK, Eom W, Yim J, et al. The effect of chronic opioid use on end-tidal concentration of sevoflurane necessary to maintain a bispectral index below 50: a prospective, single-blind study. Anesth Analg. 2017;125(1):156–161. doi:10.1213/ANE.0000000000001791
  • Dixon WJ. Staircase bioassay: the up-and-down method. Neurosci Biobehav Rev. 1991;15(1):47–50. doi:10.1016/s0149-7634(05)80090-9
  • Pace NL, Stylianou MP, Warltier DC. Advances in and limitations of up-and-down methodology: a precis of clinical use, study design, and dose estimation in anesthesia research. Anesthesiology. 2007;107(1):144–152. doi:10.1097/01.anes.0000267514.42592.2a
  • Hu P, Harmon D, Frizelle H. Patient comfort during regional anesthesia. J Clin Anesth. 2007;19(1):67–74. doi:10.1016/j.jclinane.2006.02.016
  • Jenkins K, Grady D, Wong J, Correa R, Armanious S, Chung F. Post-operative recovery: day surgery patients’ preferences. Br J Anaesth. 2001;86(2):272–274. doi:10.1093/bja/86.2.272
  • Hohener D, Blumenthal S, Borgeat A. Sedation and regional anaesthesia in the adult patient. Br J Anaesth. 2008;100(1):8–16. doi:10.1093/bja/aem342
  • Wu CL, Naqibuddin M, Fleisher LA. Measurement of patient satisfaction as an outcome of regional anesthesia and analgesia: a systematic review. Reg Anesth Pain Med. 2001;26(3):196–208. doi:10.1053/rapm.2001.22257
  • Wang YX, Mao XF, Li TF, Gong N, Zhang MZ. Dezocine exhibits antihypersensitivity activities in neuropathy through spinal mu-opioid receptor activation and norepinephrine reuptake inhibition. Sci Rep. 2017;7(1):43137. doi:10.1038/srep43137
  • Liu R, Huang XP, Yeliseev A, Xi J, Roth BL. Novel molecular targets of dezocine and their clinical implications. Anesthesiology. 2014;120(3):714–723. doi:10.1097/ALN.0000000000000076
  • Ren BX, Zong J, Tang JC, et al. Effects of intravenous analgesia with combined dezocine and butorphanol on postoperative cognitive function in elderly patients. Genet Mol Res. 2015;14(2):5571–5576. doi:10.4238/2015.May.25.8
  • Wang YH, Chai JR, Xu XJ, et al. Pharmacological characterization of dezocine, a potent analgesic acting as a kappa partial agonist and mu partial agonist. Sci Rep. 2018;8(1):14087. doi:10.1038/s41598-018-32568-y
  • Wang L, Yi Q, Ye C, Luo N, Wang E. Effects of dezocine on the reduction of emergence delirium after laparoscopic surgery: a retrospective propensity score-matched cohort study. J Pers Med. 2023;13(4):590. doi:10.3390/jpm13040590
  • Chartoff E, Sawyer A, Rachlin A, Potter D, Pliakas A, Carlezon WA. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology. 2012;62(1):167–176. doi:10.1016/j.neuropharm.2011.06.014
  • Gillman KW, Parker MF, Silva M, et al. Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression. Bioorg Med Chem Lett. 2013;23(2):407–411. doi:10.1016/j.bmcl.2012.11.094
  • Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82–88. doi:10.1016/j.biopsych.2019.06.020
  • Zamani N, Hassanian-Moghaddam H. Intravenous buprenorphine: a substitute for naloxone in methadone-overdosed patients? Ann Emerg Med. 2017;69(6):737–739. doi:10.1016/j.annemergmed.2016.12.024
  • Zamani N, Hassanian-Moghaddam H, Bayat AH, et al. Reversal of opioid overdose syndrome in morphine-dependent rats using buprenorphine. Toxicol Lett. 2015;232(3):590–594. doi:10.1016/j.toxlet.2014.12.007
  • Columb MO, Lyons G. Determination of the minimum local analgesic concentrations of epidural bupivacaine and lidocaine in labor. Anesth Analg. 1995;81(4):833–837. doi:10.1097/00000539-199510000-00030
  • Smart JA, Pallett EJ, Duthie DJ. Breath interval as a continuous measure of opioid effects of intravenous fentanyl and alfentanil. Eur J Anaesthesiol. 2003;20(6):498–500. doi:10.1017/s0265021503230805
  • Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer SL. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology. 1996;84(4):821–833. doi:10.1097/00000542-199604000-00009
  • Ferguson LM, Drummond GB. Acute effects of fentanyl on breathing pattern in anaesthetized subjects. Br J Anaesth. 2006;96(3):384–390. doi:10.1093/bja/ael011
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.